Date: Apr. 12th, 2021

Your Name: Antonio Portolés Hernández

Manuscript Title: Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia

gravis - a case report.

Manuscript number (if known): CDT-21-147

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X_None | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for lectures, presentations, | XNone | |
|-----|---|------------------------------|--------------------------|
| | | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| c | educational events | X None | |
| 6 | Payment for expert testimony | XNone | |
| | testimony | | |
| 7 | Support for attending | X None | |
| ′ | meetings and/or travel | | |
| | meetings and/or traver | | |
| | | | |
| | | | |
| 0 | Datanta ulama di tarra d | V. None | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X_None | |
| | | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | XNone | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| Ple | ease summarize the above c | onflict of interest in the f | ollowing box: |
| _ | | | |
| | None. | | |
| | | | |
| | | | |
| | | | |
| Ple | ease place an "X" next to the | following statement to | indicate vour agreement: |

Date: Apr. 12th, 2021

Your Name: Mariola Blanco Clemente

Manuscript Title: Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia

gravis - a case report.

Manuscript number (if known): CDT-21-147

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for lectures, presentations, | XNone | |
|-----|---|------------------------------|--------------------------|
| | | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| c | educational events | X None | |
| 6 | Payment for expert testimony | XNone | |
| | testimony | | |
| 7 | Support for attending | X None | |
| ′ | meetings and/or travel | | |
| | meetings and/or traver | | |
| | | | |
| | | | |
| 0 | Datanta ulama di tarra d | V. None | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X_None | |
| | | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | XNone | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| Ple | ease summarize the above c | onflict of interest in the f | ollowing box: |
| _ | | | |
| | None. | | |
| | | | |
| | | | |
| | | | |
| Ple | ease place an "X" next to the | following statement to | indicate vour agreement: |

Date: Apr. 12th, 2021

Your Name: Daniel Escribano García

Manuscript Title: Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia

gravis - a case report.

Manuscript number (if known): CDT-21-147

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X_None | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for lectures, presentations, | XNone | |
|-----|---|------------------------------|--------------------------|
| | | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| c | educational events | X None | |
| 6 | Payment for expert testimony | XNone | |
| | testimony | | |
| 7 | Support for attending | X None | |
| ′ | meetings and/or travel | | |
| | meetings and/or traver | | |
| | | | |
| | | | |
| 0 | Datanta ulama di tarra d | V. None | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X_None | |
| | | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | XNone | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| Ple | ease summarize the above c | onflict of interest in the f | ollowing box: |
| _ | | | |
| | None. | | |
| | | | |
| | | | |
| | | | |
| Ple | ease place an "X" next to the | following statement to | indicate vour agreement: |

Date: Apr. 12th, 2021

Your Name: Rocío Velasco Calvo

Manuscript Title: Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia

gravis - a case report.

Manuscript number (if known): CDT-21-147

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X_None | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for lectures, presentations, | XNone | |
|-----|---|------------------------------|--------------------------|
| | | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| c | educational events | X None | |
| 6 | Payment for expert testimony | XNone | |
| | testimony | | |
| 7 | Support for attending | X None | |
| ′ | meetings and/or travel | | |
| | meetings and/or traver | | |
| | | | |
| | | | |
| 0 | Datanta ulama di tarra d | V. None | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X_None | |
| | | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | XNone | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| Ple | ease summarize the above c | onflict of interest in the f | ollowing box: |
| _ | | | |
| | None. | | |
| | | | |
| | | | |
| | | | |
| Ple | ease place an "X" next to the | following statement to | indicate vour agreement: |

Date: Apr. 12th, 2021

Your Name: Beatriz Núñez García

Manuscript Title: Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia

gravis - a case report.

Manuscript number (if known): CDT-21-147

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Name all entities with Specifications/Comments whom you have this (e.g., if payments were made to you or to your relationship or indicate institution) none (add rows as needed)

1 All support for the present __X__None manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)
No time limit for this item.

Time frame: past 36 months

2 Grants or contracts from __X__None any entity (if not indicated in item #1 above).

| | Royalties or licenses | XNone | |
|----|--|--------|--|
| 4 | Consulting fees | XNone | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | XNone | |
| 6 | Payment for expert testimony | XNone | |
| 7 | Support for attending meetings and/or travel | XNone | |
| 8 | Patents planned, issued or pending | XNone | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | XNone | |
| 1 | O Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone | |
| 1 | 1 Stock or stock options | XNone | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | X_None | |
| 1 | 3 Other financial or non- financial interests | XNone | |

| | None. | |
|---|--|---------|
| P | lease place an "X" next to the following statement to indicate your agreement: | |
| _ | _X_I certify that I have answered every question and have not altered the wording of any of the questions of form. | on this |

Please summarize the above conflict of interest in the following box:

Date: Apr. 12th, 2021

Your Name: Juan Francisco Oteo Domínguez

Manuscript Title: Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia

gravis - a case report.

Manuscript number (if known): CDT-21-147

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | X_None | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for lectures, presentations, | XNone | |
|-----|---|------------------------------|--------------------------|
| | | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| c | educational events | X None | |
| 6 | Payment for expert testimony | XNone | |
| | testimony | | |
| 7 | Support for attending | X None | |
| ′ | meetings and/or travel | | |
| | meetings and/or traver | | |
| | | | |
| | | | |
| 0 | Datanta ulama di tarra d | V. None | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X_None | |
| | | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | XNone | |
| | financial interests | | |
| | | | |
| | | | |
| | | | |
| Ple | ease summarize the above c | onflict of interest in the f | ollowing box: |
| _ | | | |
| | None. | | |
| | | | |
| | | | |
| | | | |
| Ple | ease place an "X" next to the | following statement to | indicate vour agreement: |

Date: Apr. 12th, 2021

Your Name: Clara Salas Antón

Manuscript Title: Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia

gravis - a case report.

Manuscript number (if known): CDT-21-147

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | X None | |

| 5 | Payment or honoraria for lectures, presentations, | XNone | |
|-----|--|------------------------------|--------------------------|
| | | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| 6 | educational events | V None | |
| 6 | Payment for expert testimony | XNone | |
| | testimony | | |
| 7 | Support for attending | X None | |
| , | meetings and/or travel | | |
| | meetings and/or traver | | |
| | | | |
| | | | |
| 0 | Datanta ulama di tarra d | V. None | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X_None | |
| | | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- financial interests | XNone | |
| | | | |
| | | | |
| | | | |
| | | | |
| Ple | ease summarize the above c | onflict of interest in the f | ollowing box: |
| | | | |
| | None. | | |
| | | | |
| | | | |
| | | | |
| Ple | ease place an "X" next to the | e following statement to | indicate vour agreement: |

Date: Apr. 12th, 2021

Your Name: Míriam Méndez García

Manuscript Title: Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia

gravis - a case report.

Manuscript number (if known): CDT-21-147

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for lectures, presentations, | XNone | |
|-----|--|------------------------------|--------------------------|
| | | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| 6 | educational events | V None | |
| 6 | Payment for expert testimony | XNone | |
| | testimony | | |
| 7 | Support for attending | X None | |
| , | meetings and/or travel | | |
| | meetings and/or traver | | |
| | | | |
| | | | |
| 0 | Datanta ulama di tarra di | V. None | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X_None | |
| | | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- financial interests | XNone | |
| | | | |
| | | | |
| | | | |
| | | | |
| Ple | ease summarize the above c | onflict of interest in the f | ollowing box: |
| | | | |
| | None. | | |
| | | | |
| | | | |
| | | | |
| Ple | ease place an "X" next to the | e following statement to | indicate vour agreement: |

Date: Apr. 12th, 2021

Your Name: Javier Segovia Cubero

Manuscript Title: Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia

gravis - a case report.

Manuscript number (if known): CDT-21-147

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initia | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| | | | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for lectures, presentations, | XNone | |
|-----|--|------------------------------|--------------------------|
| | | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| 6 | educational events | V None | |
| 6 | Payment for expert testimony | XNone | |
| | testimony | | |
| 7 | Support for attending | X None | |
| , | meetings and/or travel | | |
| | meetings and/or traver | | |
| | | | |
| | | | |
| 0 | Datanta ulama di tarra di | V. None | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X_None | |
| | | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- financial interests | XNone | |
| | | | |
| | | | |
| | | | |
| | | | |
| Ple | ease summarize the above c | onflict of interest in the f | ollowing box: |
| | | | |
| | None. | | |
| | | | |
| | | | |
| | | | |
| Ple | ease place an "X" next to the | e following statement to | indicate vour agreement: |

Date: Apr. 12th, 2021

Your Name: Fernando Domínguez Rodríguez

Manuscript Title: Checkpoint inhibitor-induced fulminant myocarditis, complete atrioventricular block and myasthenia

gravis - a case report.

Manuscript number (if known): CDT-21-147

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | X None | |

| 5 | Payment or honoraria for lectures, presentations, | XNone | |
|-----|--|------------------------------|--------------------------|
| | | | |
| | speakers bureaus, | | |
| | manuscript writing or | | |
| 6 | educational events | V None | |
| 6 | Payment for expert testimony | XNone | |
| | testimony | | |
| 7 | Support for attending | X None | |
| , | meetings and/or travel | | |
| | meetings and/or traver | | |
| | | | |
| | | | |
| 0 | Datanta ulama di tarra d | V. None | |
| 8 | Patents planned, issued or | XNone | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | XNone | |
| | Safety Monitoring Board or | | |
| | Advisory Board | | |
| 10 | Leadership or fiduciary role | XNone | |
| | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | XNone | |
| | | | |
| | | | |
| 12 | Receipt of equipment, materials, drugs, medical | X_None | |
| | | | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- financial interests | XNone | |
| | | | |
| | | | |
| | | | |
| | | | |
| Ple | ease summarize the above c | onflict of interest in the f | ollowing box: |
| | | | |
| | None. | | |
| | | | |
| | | | |
| | | | |
| Ple | ease place an "X" next to the | e following statement to | indicate vour agreement: |